Fortis Healthcare (India) Ltd has announced that Fortis Healthcare Singapore Pte. Ltd ("Fortis Healthcare Singapore"), our offshore subsidiary, has acquired 85% stake in RadLink-Asia Pte Ltd ("RadLink"), an outpatient diagnostic and molecular imaging chain in Singapore, for a purchase consideration of S$62.9 million.
The transaction provides Fortis Healthcare a strong foothold in the premium diagnostics and molecular imaging segment in one of Southeast Asia's most attractive markets besides providing a complementary platform to its upcoming specialty hospital on Adam Road in Singapore.
Radlink has four main business segments; diagnostic imaging, molecular imaging, cyclotron (radio-isotopes manufacturing) and GP clinics.